Calcium Bisglycinate

Calcium bisglycinate delivers elemental calcium chelated to two glycine molecules, enabling absorption via intestinal peptide transporter pathways (PepT1) rather than the pH-dependent passive diffusion required by inorganic salts, effectively shielding the calcium ion from inhibitory dietary ligands such as phytates and oxalates. Comparative bioavailability studies indicate approximately 44% fractional absorption—roughly 1.8 times greater than calcium citrate and superior to calcium carbonate—making it the highest-bioavailability oral calcium form currently documented.

Origin & History

Calcium bisglycinate is a fully synthetic chelated mineral compound with no geographic or botanical origin; it is manufactured through a controlled chelation process in which elemental calcium is chemically bonded to two glycine molecules (the simplest amino acid) in a 1:2 molar ratio. The compound (CAS 35947-07-0, molecular formula C4H8CaN2O4, molecular weight 188.20 g/mol) is produced industrially as a white to off-white powder under pharmaceutical or food-grade conditions, typically meeting USP or food-additive specifications. It has no history in traditional agriculture or wild harvesting, as it was developed in the modern nutraceutical and food-fortification era specifically to overcome the absorption limitations of inorganic calcium salts.

Historical & Cultural Context

Calcium bisglycinate has no history in traditional medicine, ethnobotany, or cultural healing practices; it is an entirely modern pharmaceutical-grade chelate developed in the latter half of the 20th century as part of the broader amino acid chelate mineral technology pioneered by researchers such as Harvey Ashmead at Albion Laboratories in the 1970s–1980s. The underlying principle—using amino acids as mineral carriers to improve bioavailability—was inspired by the observation that minerals naturally occurring in food are often bound to organic ligands and absorbed more efficiently than isolated inorganic salts. Regulatory recognition followed commercial development: calcium bisglycinate is now listed as a permitted food additive or novel food ingredient in multiple jurisdictions including the European Union (as calcium glycinate) and is classified as Generally Recognized As Safe (GRAS) for food fortification purposes in the United States. Its development context is therefore entirely nutraceutical and food-technology driven, with no counterpart in Ayurvedic, Traditional Chinese Medicine, or Western herbal traditions.

Health Benefits

- **Bone Mineral Density Support**: Elemental calcium delivered via bisglycinate directly supplies the primary mineral constituent of hydroxyapatite [Ca10(PO4)6(OH)2], the crystalline matrix of cortical and trabecular bone; superior fractional absorption (~44%) means more calcium reaches the osteoblast-rich remodeling front compared to carbonate or citrate forms.
- **Osteoporosis and Fracture Risk Reduction**: By maintaining a positive calcium balance, bisglycinate supplementation supports suppression of parathyroid hormone (PTH)-driven osteoclastic resorption; adequate calcium intake combined with high bioavailability is associated with reduced bone turnover markers in postmenopausal populations.
- **Calcium Deficiency Correction**: The chelated form is particularly effective in individuals with achlorhydria, elderly patients, or those on proton-pump inhibitors, because unlike calcium carbonate it does not require an acidic gastric environment to dissolve, allowing effective repletion regardless of gastric pH.
- **Gastrointestinal Tolerability**: Bisglycinate's amino acid transport mechanism bypasses the luminal ionization step that can cause osmotic side effects; clinical observations and product-safety data indicate a gentler GI profile than carbonate, with lower rates of bloating and constipation at equivalent elemental doses.
- **Food and Beverage Fortification Efficacy**: Calcium bisglycinate's 205-fold greater solubility versus calcium citrate, stable pH range (6.0–9.0), and minimal sensory impact make it suitable for fortifying dairy products, plant-based milks, cereals, and juices at 5–30 mg/100 g without altering texture, color, or flavor.
- **Pregnancy and Lactation Support**: High bioavailability reduces the absolute amount required to meet the increased fetal skeletal mineralization demands of pregnancy (RDA ~1,000 mg elemental Ca/day); bisglycinate's gentle profile and amino acid carrier form make it a practical choice for prenatal supplementation.
- **Muscle and Nerve Function**: Calcium ions modulate voltage-gated calcium channels, troponin C-mediated muscle contraction, and synaptic neurotransmitter release; sustained adequate calcium status supported by highly bioavailable bisglycinate helps maintain normal neuromuscular excitability and cardiovascular rhythmicity.

How It Works

Calcium bisglycinate is absorbed primarily through the intestinal peptide transporter PepT1 (SLC15A1) located on the apical brush-border membrane of enterocytes in the duodenum and proximal jejunum, a carrier-mediated pathway normally used for di- and tripeptides that is saturable but pH-independent, circumventing the ionization step required by inorganic salts. The glycine chelation sterically shields the calcium ion from forming insoluble complexes with dietary inhibitors—phytic acid, oxalic acid, and polyphenols—that would otherwise precipitate calcium in the intestinal lumen and block passive paracellular absorption. Once inside the enterocyte, the chelate is dissociated and calcium is shuttled across the basolateral membrane via the plasma membrane Ca²⁺-ATPase (PMCA1b) and the sodium–calcium exchanger (NCX1), entering portal circulation for delivery to bone, kidney, and soft tissues. At the cellular level, adequate intracellular calcium activates calmodulin-dependent kinases, supports osteoblast differentiation through Wnt/β-catenin signaling, and downregulates PTH secretion by activating the calcium-sensing receptor (CaSR) on parathyroid chief cells, collectively reducing osteoclastic bone resorption.

Scientific Research

The evidence base for calcium bisglycinate is limited compared to calcium carbonate and citrate; large, prospective randomized controlled trials specifically using bisglycinate as the intervention and measuring hard endpoints such as bone mineral density (BMD) change or fracture incidence are lacking in the published literature. Comparative bioavailability data—including the frequently cited ~44% fractional absorption and 1.8-fold superiority over calcium citrate—derive primarily from earlier pharmacokinetic studies and textbook references (e.g., Groff & Gropper, 2000) rather than contemporary large-cohort RCTs with pre-registered protocols and rigorous blinding. A food-science study evaluating calcium bisglycinate fortification of kefir at 5–30 mg/100 g milk demonstrated preserved physicochemical parameters (pH, syneresis, sensory scores on a 1–9 scale) over 21 days of refrigerated storage, confirming technological feasibility, but this study was not designed to assess human health outcomes or provide sample-size-powered efficacy data. Overall, the evidence tier is moderate-preliminary: mechanistic and pharmacokinetic rationale is strong, food-safety data are supportive, but clinicians seeking bisglycinate-specific BMD or fracture data should recognize the current evidence gap and rely on class-level calcium supplementation literature until dedicated RCTs are published.

Clinical Summary

No large Phase III randomized controlled trials have been published specifically investigating calcium bisglycinate as a named intervention for osteoporosis, fracture prevention, or bone mineral density, limiting direct clinical extrapolation. Comparative absorption studies position bisglycinate as the highest-bioavailability oral calcium salt (~44% fractional absorption versus ~32% for citrate and ~22–27% for carbonate in low-acid conditions), though these figures originate from small pharmacokinetic crossover designs rather than multicenter RCTs powered for clinical endpoints. The most specific applied study evaluated kefir fortification (5–30 mg elemental calcium per 100 g milk) and found no detrimental changes in acidity, syneresis, or consumer-rated sensory attributes over a 21-day shelf-life trial, confirming functional utility in food matrices without characterizing clinical outcomes. Confidence in the bioavailability advantage is moderate and mechanistically well-supported; confidence in downstream clinical benefits (fracture reduction, BMD preservation) is inferred from the broader calcium supplementation literature and requires bisglycinate-specific trial confirmation.

Nutritional Profile

Calcium bisglycinate provides elemental calcium as its sole nutritionally active mineral, contributing approximately 210 mg elemental calcium per gram of bisglycinate salt (theoretical: Ca molecular weight 40.08 ÷ bisglycinate MW 188.20 ≈ 21.3% elemental calcium). The two glycine ligands per molecule (each ~75 g/mol) contribute negligible protein calories or amino acid load at typical supplemental doses (≤500 mg elemental Ca delivers <2 g glycine). No significant macronutrient, lipid, carbohydrate, vitamin, or phytochemical content is present; the compound is essentially a pure mineral chelate. Bioavailability factors strongly favor bisglycinate: the chelated structure resists precipitation by dietary phytates (found in grains, legumes) and oxalates (spinach, tea), and absorption is independent of gastric acid pH, distinguishing it from calcium carbonate which requires an acidic environment for dissolution. Fractional absorption of approximately 44% compares favorably to calcium citrate (~32–36%), calcium carbonate (~22–40% acid-dependent), and calcium gluconate (~27%).

Preparation & Dosage

- **Capsules/Tablets**: 250–500 mg elemental calcium per serving (note: elemental calcium content is approximately 21% of bisglycinate salt weight by mass); typically taken 1–2 times daily with meals to co-activate intestinal transporters.
- **Powder (Bulk/Functional Food)**: USP-grade white to off-white powder, pH 6.0–9.0 in solution; shelf life approximately 3 years stored at ≤20°C in sealed, moisture-controlled containers; used at 5–30 mg elemental calcium per 100 g in dairy fortification.
- **Liquid Supplements**: Dissolved in aqueous matrices for beverages or functional foods; high solubility (205× calcium citrate) allows clear or near-clear solutions at typical fortification concentrations.
- **Standard Supplemental Dose**: 500–1,200 mg elemental calcium daily in divided doses (≤500 mg per dose for optimal absorption kinetics); dosing above 500 mg per single administration does not proportionally increase fractional absorption.
- **Timing**: With food is preferred to stimulate bile and pancreatic secretions that facilitate enterocyte uptake; bisglycinate retains superiority over carbonate even in fasting/low-acid states, but food co-ingestion remains best practice.
- **Fortification Level**: 5–30 mg elemental calcium per 100 g dairy product demonstrated safe and organoleptically neutral in fermented milk studies; higher fortification levels require formulation-specific stability testing.
- **Standardization**: Commercial USP-grade bisglycinate is standardized to declared elemental calcium content verified by chelation or ICP-MS assay; reputable manufacturers provide certificates of analysis confirming heavy-metal absence.

Synergy & Pairings

Calcium bisglycinate exhibits the most clinically documented synergy with vitamin D3 (cholecalciferol), which upregulates intestinal calbindin-D9k and TRPV6 calcium channel expression, further amplifying active transcellular calcium transport and increasing net calcium retention; this pairing is the standard of care in osteoporosis prevention protocols. Co-administration with vitamin K2 (menaquinone-7, MK-7) is mechanistically rational because K2 activates matrix Gla protein (MGP) and osteocalcin via γ-carboxylation, directing absorbed calcium toward bone matrix mineralization and away from arterial soft-tissue calcification, forming the classic calcium–D3–K2 bone-health stack. Magnesium glycinate is frequently combined with calcium bisglycinate because adequate magnesium is required for PTH secretion and activation of 25-hydroxyvitamin D to calcitriol (1,25(OH)2D3), and the glycinate carrier form of both minerals reduces competitive absorption interference that can occur with high-dose inorganic magnesium and calcium co-ingestion.

Safety & Interactions

At recommended supplemental doses (500–1,200 mg elemental calcium/day), calcium bisglycinate is considered well-tolerated; the chelated form produces fewer gastrointestinal complaints (constipation, bloating, gas) than calcium carbonate, and the MSDS classifies the bulk compound as low acute toxicity with no explosive or strongly flammable properties at ambient conditions. Hypercalcemia risk arises at total elemental calcium intakes substantially exceeding the tolerable upper intake level (UL: 2,000–2,500 mg/day for adults per the Institute of Medicine), manifesting as nausea, polyuria, nephrolithiasis, and soft-tissue calcification; bisglycinate's superior absorption theoretically warrants vigilance against inadvertent over-supplementation relative to lower-bioavailability forms. Drug interactions relevant to all calcium supplements include: reduced absorption of fluoroquinolone and tetracycline antibiotics (space doses by ≥2 hours), impaired absorption of bisphosphonates (alendronate, risedronate; take calcium ≥30 minutes after), potential antagonism of thyroid hormone (levothyroxine; separate by ≥4 hours), and additive hypercalcemia risk with thiazide diuretics and vitamin D megadosing. Calcium bisglycinate is considered appropriate for use in pregnancy and lactation given its favorable absorption profile, though total daily calcium from all dietary and supplemental sources should be tracked to remain within trimester-specific RDA (1,000 mg/day) and UL thresholds; individuals with a history of hypercalcemia, hyperparathyroidism, or calcium-containing kidney stones should use under medical supervision.